- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05494632
Interaural Mismatch in SSD CI Users
Effects of Interaural Loudness and Pitch Mismatch on SSD-CI Performance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Effective binaural processing depends on similar loudness growth functions at each ear (Francart et al, 2013, Blamey et al, 2000). The use of interaural level differences (ILDs), perceived as loudness differences, to locate sound is critical given the inability of cochlear implant (CI) recipients to use interaural time differences (ITDs) in binaural processing (Francart et al, 2013, Litovsky et al, 2012). In CI recipients with single-sided deafness (SSD), perceived interaural loudness differences may not be valid indicators of interaural level differences because the CI compresses amplitude (Dorman et al, 2015). Studies suggest better preservation of ILDs may contribute to improved localization and understanding in noise. Since SSD-CI recipients use only one device, an approach to improve their use of ILDs is to match perceived loudness at each ear (Buss et al, 2018).
Binaural processing is also affected when signals of equal frequency are not matched in pitch at each ear. In bilateral CI recipients, we found that the greater the pitch mismatch between ears, the poorer the speech understanding in noise. We want to extend this work to SSD-CI recipients. Through CI program modifications, we aim to decrease the pitch and loudness mismatch between the CI ear and the normal hearing ear to improve binaural listening abilities, specifically speech understanding in noise and sound localization.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Laura K Holden, AuD
- Phone Number: 314-362-7246
- Email: laurakholden@wustl.edu
Study Contact Backup
- Name: Jill B Firszt, PhD
- Phone Number: 314-362-4760
- Email: firsztj@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Principal Investigator:
- Jill B Firszt, PhD
-
Contact:
- Laura K Holden, AuD
- Phone Number: 314-362-7246
- Email: laurakholden@wustl.edu
-
Contact:
- Jill B Firszt, PhD
- Phone Number: 314-362-4760
- Email: firsztj@wustl.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants for the proposed study will be adults with single-sided deafness. Participants will have at least 6 months experience with their cochlear implant or will be newly implanted with the cochlear implant.
Inclusion criteria for the experienced CI user group and the newly implant group are as follows:
- 18 years of age and older
- Postlingual onset of SSD
- Pure tone average (PTA) at 500, 1000, and 2000 Hz of less than or equal to 30 dB HL in the contralateral ear, known as the normal hearing ear
- Implanted with or chosen to be implanted with a Nucleus cochlear implant
- Full insertion of electrode array
Exclusion Criteria:
- • Not meeting the inclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
CI speech processor programming
|
We will modify the CI speech processor program to reduce interaural loudness and pitch mismatches.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Speech understanding in noise
Time Frame: 6 months
|
Testing in noise will be obtained using the R-Space test which simulates listening in a noisy restaurant.
The score is a signal-to-noise ratio that reflects 50% speech understanding in noise.
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jill B Firszt, PhD, Washington University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 202206085
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Outcomes
-
Zimmer BiometActive, not recruitingClinical Outcomes | Survivorship | Safety | Functional Outcomes | Radiological OutcomesUnited States
-
Third Military Medical UniversityCompletedPerioperative Outcomes | Oncological OutcomesChina
-
ModernaTX, Inc.CompletedPregnancy | Maternal Outcomes | Infant OutcomesUnited States
-
University of LiegeCompletedIntraoperative Outcomes | Postoperative Outcomes
-
Teachers College, Columbia UniversityColumbia UniversityNot yet recruitingAdverse Childhood Experiences | Mental Health Outcomes | Perceived School Safety | Educational Outcomes
-
Peking Union Medical College HospitalUnknown
-
Stony Brook UniversityRecruiting
-
Sophiahemmet UniversityKarolinska Institutet; Göteborg UniversityCompleted
-
Cedars-Sinai Medical CenterCompleted
-
University of ChicagoCompletedNonhealth Outcomes
Clinical Trials on Treatment-modifications to CI speech processor program
-
Lawson Health Research InstituteUnknownParkinson Disease | Speech DisordersCanada
-
University of Colorado, DenverThe Leona M. and Harry B. Helmsley Charitable TrustRecruitingHypoglycemia | Menstruation Disturbances | Type 1 Diabetes | Hyperglycaemia Due to Type 1 Diabetes MellitusUnited States
-
Children's Hospital of PhiladelphiaAgency for Healthcare Research and Quality (AHRQ); Devereux Center for Effective...Completed
-
VA Office of Research and DevelopmentRecruiting
-
Lund UniversitySuspended
-
University of FloridaNational Institute on Drug Abuse (NIDA)Withdrawn
-
University of CologneUnknownOppositional Defiant DisorderGermany
-
Shanghai Children's Medical CenterNot yet recruiting
-
Keller Army Community HospitalUniformed Services University of the Health SciencesRecruitingPain | Telemedicine | Running | KneeUnited States
-
Children's Hospital of PhiladelphiaAgency for Healthcare Research and Quality (AHRQ); Devereux Center for Effective...Enrolling by invitation